Most neonates born with congenital hypothyroidism (CH) have normal appearance and no detectable physical signs. Hypothyroidism in the newborn period is almost always overlooked and delayed diagnosis leads to the most severe outcome of CH, mental retardation, emphasizing the importance of neonatal screening. Blood spot T4 or TSH or both can be used in neonatal screening for CH. The latter, which is more sensitive, is not cost effective, so the first two are used in different programs in the world. TSH screening was shown to be more specific in the diagnosis of CH; T4 screening is more sensitive in detecting newborns especially with rare hypothalamic-pituitary hypothyroidism, but less specific with a high frequency of false positives mainly in low birth weight and premature infants. The time at which the sample is taken may vary between centers, with the majority taking blood from a heel prick after 24 hours of age to minimize the false positive high TSH due to the physiological neonatal TSH surge that elevates TSH levels and causes dynamic T4 and T3 changes in the first 1 or 2 days after birth. Early discharge of mothers postpartum has increased the ratio of false positive TSH elevations. Although transient hypothyroidism may occur frequently, all suspected infants should be treated as having CH for the first 3 years of life, taking into account the risks of mental retardation. A reevaluation after 3 years is needed in such patients. The goal of initial therapy in CH
INTRODUCTION
Congenital hypothyroidism (CH) is the commonest treatable cause of mental retardation. CH is usually sporadic and occurs in one in 3,000-4,000 infants. Most infants with CH are normal at birth and show no signs, emphasizing the importance of early detection of CH 12 .
Newborn screening for CH is one of the major achievements of preventive medicine. Although since 1972, the problem of CH has been resolved in developed countries by the implementation of neonatal screening for CH, the problem exists for developing countries which still have no neonatal screening programs for CH 2, 3 . Since diagnosis based on clinical findings is delayed in most instances because of few symptoms and signs, hypothyroidism in the newborn period is almost always overlooked and delayed diagnosis leads to the most severe outcome of CH, mental retardation. In a Danish study, it was emphasized that only 10% of affected infants were diagnosed within the first month of life, and 35% within 3 months. Seventy percent were diagnosed within the first year , while in the remainder the diagnosis was delayed to the 3 rd and 4 th years of life 4 . In a retrospective analysis of 1,000 cases of CH in Turkey, the mean age at diagnosis was 49 months and only 3.1% of cases were diagnosed within the first month, whereas 55.4% were diagnosed after 2 years of age 5 .
The first CH screening was performed by Dussault and Laberge 6 ' 7 in Quebec, Canada, in 1972. They detected seven hypothyroid infants among 47,000 newborns over 3 years. The high frequency of false positives delayed the diagnosis and increased the cost, and they arranged the cutoff values used for recall. The infants recalled were subjected to thyroid hormones and thyroid stimulating hormone (TSH) blood studies. In the meantime, radioactive labeled antibodies for determining thyroxine (T4) in dried blood spots became available and began to be used regionally in the USA and Europe. These tests were run in parallel to screening programs for phenylketonuria (PKU). In the initial report by Dussault et α/. 8 , the method was recommended as a confirmatory test, and that it would miss cases with hypothlamic-pituitary hypothyroidism which they reported to be 10% of cases. In 1976, it was reported in The Lancet that cord blood TSH measurements were shown to have greater sensitivity and specificity than cord blood T4 and blood spot T4 (collected from 3-4 days old newborns), and false positives were high in the T 4 method with high costs 9 . Walfish 9 suggested routine T4 screening supplemented by TSH estimation be used in mass screening.
Blood spot T4 or TSH or both can be used in neonatal screening for CH. The latter, which is more sensitive, is not cost effective, so one of the first two is used in different programs in the world. Some North American programs prefer primary T4 testing supplemented with TSH, whereas other American and European programs prefer primary TSH in the detection of CH 10 " 14 . TSH screening was shown to be more specific in the diagnosis of CH; T4 screening is more sensitive in detecting newborns especially with rare hypothalamicpituitary hypothyroidism, but less specific with a high frequency of false positives mainly in low birth weight and premature infants. Infants with thyroxine binding globulin (TBG) deficiency who are euthyroid can be detected by T 4 screening.
The Neonatal Thyroid Screening Conference held in Tokyo in 1982 recommended neonatal screening programs oriented to detect infants with elevated serum concentrations of TSH 15 . They suggested that this could be accomplished by measuring TSH in filter paper blood spots or by measuring T 4 supplemented by TSH in the same blood spot of infants who have T4 values in the lower 3 rd to 10 th percentile.
METHODS FOR SCREENING
The aim is to detect ail cases with the disease as early as possible, with acceptable cost-benefit ratio, and to avoid false positive results. Today, more sensitive and automated methods (chemiluminescence, fluoroimmunoassay, etc.) for determining both T 4 and TSH in dried blood spots are available 16 " 21 . They have increased sensitivity and specificity. Besides the development of more accurate test programs, some children may still be missed in any screening program. The reasons could be failure of sample collection, unsatisfactory samples, misinterpretation of samples, and unsatisfactory recalls.
The time at which the sample is taken may vary between centers, with the majority taking blood from a heel prick after 24 hours of age to minimize the false positive high TSH due to the physiological neonatal TSH surge that elevates TSH levels and causes dynamic T 4 and triiodothyronine (T3) changes in the first 1 or 2 days after birth. Early discharge of mothers postpartum has increased the ratio of false positive TSH elevations. The difficulty in screening for CH using cord blood samples is in the handling and transport of the samples, making it an impractical method for mass screening 22 .
Whichever method is used, an initial TSH >50 μυ/l is often indicative of permanent CH, whereas TSH between 20 and 49 μυ/l is frequently a false positive or represents transient hypothyroidism. Transient CH is particularly common in premature infants in borderline iodine deficient areas. When TSH measurement is used as the primary method, and 15 μυ/l (immunofluorometric method) or 20 μυ/l (radioimmunological method) is used as the cut-off, the recall rate is as low as 0.05%. Iodine deficiency can increase false positives and increase the recall rate. The sensitivity of TSH estimation for CH is suggested to be 97.5% and specificity 99% 23 · 24 .
Neonatal screening with primary TSH method detects:
• overt and compensated primary hypothyroidism.
Neonatal screening with primary TSH method misses:
• secondary/tertiary hypothyroidism;
• TBG deficiency;
• premature infants with very low body weight with delayed TSH surge.
In primary T4 screening, performed in some states of the USA, cut-off at the 10 th percentile resulted in 1.5% missed cases, whereas cut-off at the 5 th percentile of T4 values resulted in 3.5% missed cases. Only 0.2% of cases were missed using the 20 th percentile as a cut-off, but of course with increased cost in terms of repeat testing 25 . Optimal screening requires initial T4 determination to be followed by TSH determinations on low T 4 samples.
Neonatal screening with primary T 4 method detects:
• overt primary hypothyroidism;
• secondary/tertiary hypothyroidism (one in 50,000-100,000 live births);
• hypothyroxinemia in sick and preterm newborns;
• Hyperthyroxinemia.
Neonatal screening with primary T 4 method misses:
• compensatory hypothyroidism with subnormal T4 and elevated TSH levels;
• transient hyperthyrotropinemia when iodine deficiency is present.
The reliability of the laboratories is as crucial as the reliability of the detection methods (with emphasis on sensitivity, specificity and positive predictive value). According to the recommendations of the Working Group of Neonatal Screening of ESPE (European Society for Paediatric Endocrinology), screening should be conducted in centralized laboratories covering 100,000 newborns per year 26 " 28 . These laboratories should participate in international control programs.
NEONATAL SCREENING RESULTS

Hypothyroxinemia (low T 4 and normal TSH)
This occurs most commonly in premature infants, in whom it is found in 50% of neonates of less than 30 weeks gestation 26 . Screening programs that employ primary TSH analysis will miss these infants because of normal TSH levels. Often the free T 4 is less affected than the total T4. The reasons for the hypothyroxinemia of prematurity are complex. In addition to hypothalamo-pituitary immaturity, there are low TBG levels and decreased conversion of T 4 to T3 in premature infants. Numerous studies have shown that there is a correlation between the degree of lowering of T4 and negative outcomes, for both mortality and developmental problems. Systematic supplementation of all low birth weight infants is not recommended at this time 23 ' 29, 30 .
Other causes of low T4 in the face of normal TSH are euthyroid sick syndrome, TBG deficiency, laboratory errors and central hypothyroidism 3 . Immature liver function, undernutrition and illness are the reasons for low T4 and normal TSH levels in euthyroid sick syndrome. Euthyroid sick syndrome may be seen in sick term newborns as well 23 . TBG deficiency is an X-linked condition uncovered only by screening programs using a primary T4 approach. It does not require treatment since the plasma levels of free thyroid hormone levels are normal and the infants are euthyroid. Its incidence is estimated to be one in 2,800 31 . TBG deficiency should be suspected especially in male infants with low T4 and normal TSH, and can be confirmed by measuring TBG serum levels. Loss of protein from nephrotic syndrome may also lead to low total T4. Errors in measurement may be caused by errors in sample gathering, impregnation with water due to improper sample handling, less amount of blood spot, or extremes of hematocrit values which adversely affect the measurements.
In a term neonate with low free T4 but normal TSH level, true central hypothyroidism, which is quite rare, should be ruled out. Mutations in the gene coding for the beta subunit of TSH or the TRH receptor could be the cause 32, 33 . Central hypothyroidism could be present together with other anterior pituitary hormone deficiencies: hypoglycemia, microphallus, prolonged jaundice, and/or cryptorchidism 34 " 36 .
Isolated hyperthyrotropinemia (normal T4 and elevated TSH)
Elevated TSH despite a normal or low normal T4 indicates inadequate hormone production. It is most common in premature infants. Although some neonates have compensated hypothyroidism, the etiology is not clear in the others. In infants discharged early (in the first day or two), TSH values are found elevated because of a cold-induced TSH surge. It can be a transient finding due to goitrogens, iodine deficiency, or medications. Genetic defects of hormone biosynthesis and also dysgenesis, especially ectopia, could be the cause. Elevated TSH with normal T4 levels can persist for 37 years .
Low T 4 and elevated TSH
The most common cause is primary CH. There might be transient cases, shown in Table 1 . The goal of initial therapy in CH is to minimize neonatal central nervous system exposure to hypothyroidism by normalizing thyroid function, as reflected by T4 and TSH levels, as rapidly as possible. Some studies have demonstrated that even a short period of 1-3 weeks of neonatal hypothyroidism before initiation of treatment can negatively affect development 41 ' 42 . In the first 10 years of neonatal screening, the recommendations for initial L-thyroxine substitution dose ranged from 5-8 μg/kg/day. Later, it was seen, in many European countries and the USA, that the use of higher initial doses led to more rapid normalization of T4 and TSH and a better long-term outcome. A starting dose of sodium L-thyroxine of about 12-17 μg/kg/ day is suggested to achieve rapid normalization of thyroid function, especially in severe forms of CH. L-Thyroxine tablets may be crushed and administered with juice or milk formula, but care should be taken that all the medicine has been swallowed. L-Thyroxine should be given once daily before breakfast and should not be given with substances that interfere with its absorption, such as iron, soya or fiber. Liquid preparations are unstable and should not be used 1 ' 41 . Changes in dose should be arranged under the light of frequent laboratory tests. Follow-up of patients with CH should include frequent thyroid function tests. The American Academy of Pediatrics recommends the following schedule for laboratory evaluations:
• at 2 and 4 weeks after the initiation of L-thyroxine treatment;
• every 1 -2 months during the first year of life;
• every 2-3 months between 1 and 3 years of age;
• every 3-12 months thereafter until growth is completed;
• at more frequent intervals when compliance is questioned or abnormal values are obtained 43 ' 44 .
IODINE DEFICIENCY
Iodine deficiency is the most important cause of CH worldwide. Iodine deficiency is a problem that affects almost one billion people despite efforts for eradication. Iodine is essential for thyroid hormone synthesis and is present in soil, water and air. Iodine deficiency disorders (IDD), which Were referred to as endemic goiter up to 30 years ago, refer to iodine deficiency that can be prevented by ensuring an adequate intake of iodine in the population 45 .
Goiter is the most frequent and visible manifestation of IDD and is an important health problem. IDD affect intellectual growth in neonates and children, and almost 20 million people living in developing countries have some degree of brain damage due to the effects of iodine deficiency (ID). ID in the mother results in deficiency in the neonate. The most striking feature of ID is endemic cretinism. Severe ID causes endemic goiter and cretinism, increased perinatal death, decreased fertility rate, and increased infant mortality. Combined iodine and selenium deficiency causes a severe form of cretinism in some areas. Two types of endemic cretinism have been defined 46 " 48 . In neurological cretinism, the number of neuronal cells is decreased, and brain weight is reduced. Myxedematous cretinism has a less severe degree of mental retardation than neurological cretinism. ID in children is characteristically associated with goiter. Goiter rate increases with age and reaches a maximum at adolescence 49 " 51 .
Iodine is present in the human body in minute amounts (10-20 μg) . The recommended dietary allowance is 60-100 μg/daily for children 1-10 years of age and 100 pg/daily for adolescents and adults. Urinary iodine (UI) excretion provides a measure of the nutritional status of iodine in a population. Dietary iodine intake is positively correlated with its urinary excretion in iodine replete areas. 24-hour iodine excreted in the urine shows the iodine nutritional status, but it is impractical and can be unreliable. If nutrition is adequate the UI/creatinine ratio is considered a more reliable measure of iodine excretion than random spot UI concentration measurements, since there are variations in iodine intake 52 ' 53 . There are several methods used to detect iodine in urine with different sensitivities; spectrophotometry, HPLC, mass spectrometry, and laser spectrometry 54 ' 55 . UI excretion of 50-99 pg/l is defined as mild iodine deficiency, 20-49 pg/l is defined as moderate iodine deficiency, and UI excretion <20 pg/l is severe iodine deficiency (Table 2) 56,57 . The daily recommended level of salt is 3-5 gram. The level of iodization of salt has to be sufficient to cover the requirement together with losses from the point of production to the point of consumption. The packing of salt is important; it loses some of its activity with boiling. Iodized salt was used for the first time in the 1920s in Switzerland and the USA and in the 1950s in Europe. However, despite iodization programs ID still exists in many parts of the world 58 " 61 .
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Problems with the iodization of salt are :
• not reaching all target communities;
• a plethora of small-scale salt producers makes salt iodization programs difficult to implement in some countries;
• some salt producers are unwilling to pay for potassium iodate, which is the recommended agent for iodization, or use smaller amounts than necessary;
• frequent unacceptable variations in the quality of iodized salt;
• some iodization programs are not adequately monitored;
• lack of laboratory facilities in many countries for monitoring salt and urinary iodine levels;
• a transient increase in the incidence of hyperthyroidism in some countries after salt iodization.
b. Iodized oil
Iodized oil (lipiodol) was first used in Papua New Guinea. A single dose iodized oil injection (4 ml) corrects iodine deficiency for a period of 4.5 years 63 . Refrigeration is not required and the cost is low compared to iodized salt. It can also be taken orally 62 . Iodized oil should be used in severe IDD areas until an effective program is introduced.
c. Iodized bread, iodized milk, iodized water, iodine tablets
These are used in different countries as iodine 64, 65 sources
